{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:24:24Z","timestamp":1770510264602,"version":"3.49.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s40268-013-0019-3","type":"journal-article","created":{"date-parts":[[2013,6,12]],"date-time":"2013-06-12T13:22:23Z","timestamp":1371043343000},"page":"159-164","source":"Crossref","is-referenced-by-count":31,"title":["Risk of Falling and Hypnotic Drugs: Retrospective Study of Inpatients"],"prefix":"10.1007","volume":"13","author":[{"given":"Kyoko","family":"Obayashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiko","family":"Kurabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihisa","family":"Nojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyuki","family":"Hara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koujirou","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,13]]},"reference":[{"key":"19_CR1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1365-2125.2010.03613.x","volume":"69","author":"H Shuto","year":"2010","unstructured":"Shuto H, Imakure O, Imakyure O, Matsumoto J, Egawa T, Ying J, Hirakawa M, Kataoka Y, Yanagawa T. Medication use as a risk factor for inpatient falls in an acute care hospital: a case-crossover study. Br J Clin Pharmacol. 2010;69:535\u201342.","journal-title":"Br J Clin Pharmacol"},{"key":"19_CR2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/pds.686","volume":"11","author":"CI Neutel","year":"2002","unstructured":"Neutel CI, Perry S, Maxwell C. Medication use and risk of falls. Pharmacoepimemiol Drug Saf. 2002;11:97\u2013104.","journal-title":"Pharmacoepimemiol Drug Saf"},{"key":"19_CR3","doi-asserted-by":"crossref","unstructured":"Rubenstein LZ, Josephson KR, Robbins AS. Falls in the nursing home. Ann Intern Med. 1994;121:442-51.","DOI":"10.7326\/0003-4819-121-6-199409150-00009"},{"key":"19_CR4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2165\/00002512-199812010-00005","volume":"12","author":"RG Cumming","year":"1998","unstructured":"Cumming RG. Epidemiology of medication-related falls and fractures in the elderly. Drugs Aging. 1998;12:43\u201353.","journal-title":"Drugs Aging"},{"key":"19_CR5","doi-asserted-by":"crossref","unstructured":"Nyberg L, Gustafson Y, Janson A, Sandman PO, Eriksson S. Incidence of falls in three different types of geriatric care. A Swedish prospective study. Scand J Soc Med. 1997;25:8-13.","DOI":"10.1177\/140349489702500103"},{"key":"19_CR6","doi-asserted-by":"crossref","first-page":"3303","DOI":"10.1001\/jama.1989.03430230088031","volume":"262","author":"WA Ray","year":"1989","unstructured":"Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989;262:3303\u20137.","journal-title":"JAMA"},{"issue":"21","key":"19_CR7","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/archinternmed.2009.357","volume":"169","author":"JC Woolcott","year":"2009","unstructured":"Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Intern Med. 2009;169(21):1952\u201360.","journal-title":"Arch Intern Med"},{"key":"19_CR8","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1046\/j.1532-5415.2002.50453.x","volume":"50","author":"KE Ensrud","year":"2002","unstructured":"Ensrud KE, Blackwell TL, Mangione CC, Schwartz AV, Hanlon JT, Nevitt MC. Central nervous system-active medications and risk for falls in older women. J Am Geriatr Soc. 2002;50:1629\u201337.","journal-title":"J Am Geriatr Soc"},{"issue":"9","key":"19_CR9","first-page":"698","volume":"19","author":"WB Mendelson","year":"1996","unstructured":"Mendelson WB. The use of sedative\/hypnotic medication and its correlation with falling down in the hospital. Sleep. 1996;19(9):698\u2013701.","journal-title":"Sleep"},{"key":"19_CR10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(97)09528-7","volume":"351","author":"B Liu","year":"1998","unstructured":"Liu B, Anderson G, Mittman N, To T, Axcell T, Shear N. Use of selective serotonin-reuptake inhibitors of tricyclic antidepressants and risk of hip fractures in elderly people. Lancet. 1998;351:1303\u20137.","journal-title":"Lancet"},{"key":"19_CR11","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJM199809243391303","volume":"339","author":"PB Thapa","year":"1998","unstructured":"Thapa PB, Gideon P, Cost TW, Milam AB, Ray WA. Antidepressants and the risk of falls among nursing home residents. New Engl J Med. 1998;339:875\u201382.","journal-title":"New Engl J Med"},{"key":"19_CR12","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/02813439508996778","volume":"13","author":"H Luukinen","year":"1995","unstructured":"Luukinen H, Koski K, Laippala P, Kivela SL. Predictors for recurrent falls among the home-dwelling elderly. Scand J Prim Health Care. 1995;13:294\u20139.","journal-title":"Scand J Prim Health Care"},{"key":"19_CR13","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00002018-199717020-00003","volume":"17","author":"I Verhaeverbeke","year":"1997","unstructured":"Verhaeverbeke I, Mets I. Drug-induced orthostatic hypotension in the elderly: avoiding its onset. Drug Saf. 1997;17:105\u201318.","journal-title":"Drug Saf"},{"key":"19_CR14","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1532-5415.1999.tb01898.x","volume":"47","author":"RM Leipzig","year":"1999","unstructured":"Leipzig RM, Cumming RG, Tinetti ME. Drugs and falls in older people: a systematic review and meta-analysis. I: psychotropic drugs. J Am Geriatr Soc. 1999;47:30\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"19_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00019052-200302000-00003","volume":"16","author":"BR Bloem","year":"2003","unstructured":"Bloem BR, Steijns JA, Smits-Engelsman BC. An update on falls. Curr Opin Neurol. 2003;16:15\u201326.","journal-title":"Curr Opin Neurol"},{"key":"19_CR16","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","volume":"401","author":"U Rudolph","year":"1999","unstructured":"Rudolph U, Crestani F, Benke D, Brunig I, Benson JA, Fritschy J-M, Martin JR, Bluethmann H, Mohler H. Benzodiazepine actions mediated by specific \u03b3-aminobutyric acid A receptor subtypes. Nature. 1999;401:796\u2013800.","journal-title":"Nature"},{"key":"19_CR17","doi-asserted-by":"crossref","first-page":"7243","DOI":"10.1021\/jm800889m","volume":"51","author":"SM Hanson","year":"2008","unstructured":"Hanson SM, Morlock EV, Satyshur KA, Czajkowski C. Structural requirements for eszopiclone and zolpidem binding to the gamma-aminobutyric acid type-A (GABA(A)) receptor are different. J Med Chem. 2008;51:7243\u201352.","journal-title":"J Med Chem"},{"key":"19_CR18","doi-asserted-by":"crossref","unstructured":"Gibson MJ. Falls in later life. In: Improving the health of older people: a world view. Oxford University Press, Oxford; 1990. p. 296\u2013315.","DOI":"10.1093\/oso\/9780192617927.003.0018"},{"key":"19_CR19","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1248\/yakushi.128.1355","volume":"128","author":"M Tanaka","year":"2008","unstructured":"Tanaka M, Suemaru K, Ikegawa Y, Tabuchi N, Araki H. Relationship between the risk of falling and drugs in an academic hospital. Yakugaku Zasshi. 2008;128:1355\u201361.","journal-title":"Yakugaku Zasshi"},{"key":"19_CR20","first-page":"143","volume":"25","author":"M Yasui","year":"2005","unstructured":"Yasui M, Kato A, Kanemasa T, Murata S, Nishitomi K, Koike K, Tai N, Shinohara S, Tokomura M, Horiuchi M, Abe K. Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes. Nihon Shinkei Seishin Yakurigaku Zasshi. 2005;25:143\u201351.","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi"},{"key":"19_CR21","first-page":"93","volume":"4","author":"GG Pascal","year":"2001","unstructured":"Pascal GG, Shirakawa K. Zolpidem: objectives, strategy and medicinal chemistry. Jpn J Clin Psychopharmacol. 2001;4:93\u20137.","journal-title":"Jpn J Clin Psychopharmacol"},{"key":"19_CR22","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1254\/fpj.119.111","volume":"119","author":"K Shirakawa","year":"2002","unstructured":"Shirakawa K. Pharmacological profile and clinical effect of zolpidem (Myslee tablets), a hypnotic agent. Nippon Yakurigaku Zasshi. 2002;119:111\u20138.","journal-title":"Nippon Yakurigaku Zasshi"},{"key":"19_CR23","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/S0014-2999(01)01502-3","volume":"434","author":"H Noguchi","year":"2002","unstructured":"Noguchi H, Kitazumi K, Mori M, Shiba T. Binding and neuropharmacological profile of zaleplon, a novel nonbenzodiazepine sedative\/hypnotic. Eur J Pharmacol. 2002;434:21\u20138.","journal-title":"Eur J Pharmacol"},{"key":"19_CR24","first-page":"970","volume":"43","author":"KL Hadingham","year":"1993","unstructured":"Hadingham KL, Wingrove P, Le Bourdelles B, Palmer KJ, Ragan CI, Whiting PJ. Cloning of cDNA sequences encoding human alpha 2 and alpha 3 gamma-aminobutyric acid A receptor subunits and characterization of the benzodiazepine pharmacology of recombinant alpha 1-, alpha 2-, alpha 3-, and alpha 5-containing human gamma-aminobutyric acid A receptors. Mol Pharmacol. 1993;43:970\u20135.","journal-title":"Mol Pharmacol"},{"key":"19_CR25","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1254\/jjp.42.189","volume":"42","author":"Y Watanabe","year":"1986","unstructured":"Watanabe Y, Shibuya T, Khatami S, Salafsky B. Comparison of typical and atypical benzodiazepines on the central and peripheral benzodiazepine receptors. Jpn J Pharmacol. 1986;42:189\u201397.","journal-title":"Jpn J Pharmacol"},{"key":"19_CR26","first-page":"435","volume":"293","author":"DJ Greenblatt","year":"2000","unstructured":"Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Durol AL, Harrel-Joseph LM, Shader RI. Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. J Pharmacol Exp Ther. 2000;293:435\u201343.","journal-title":"J Pharmacol Exp Ther"},{"key":"19_CR27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0009-9236(98)90139-4","volume":"64","author":"DJ Greenblatt","year":"1998","unstructured":"Greenblatt DJ, Harmatz JS, von Moltke LL, Ehrenberg BL, Harrel L, Corbett K, Counihan M, Graf JA, Darwish M, Mertzanis P, Martin PT, Cevallos WH, Shader RI. Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo. Clin Pharmacol Ther. 1998;64:553\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"19_CR28","doi-asserted-by":"crossref","first-page":"2S","DOI":"10.1016\/0002-9343(90)90278-L","volume":"88","author":"LE Gustavson","year":"1990","unstructured":"Gustavson LE, Carrigan PJ. The clinical pharmacokinetics of single doses of estazolam. Am J Med. 1990;88:2S\u20135S.","journal-title":"Am J Med"},{"key":"19_CR29","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/j.1365-2125.2006.02707.x","volume":"63","author":"TI Saari","year":"2007","unstructured":"Saari TI, Laine K, Leino K, Valtonen M, Neuvonen PJ, Olkkola KT. Effect of voriconazole on the pharmacokinetics and pharmacodynamics of zolpidem in healthy subjects. Br J Clin Pharmacol. 2007;63:116\u201320.","journal-title":"Br J Clin Pharmacol"},{"key":"19_CR30","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.0306-5251.2003.01852.x","volume":"56","author":"JO Olubodun","year":"2003","unstructured":"Olubodun JO, Ochs HR, von Moltke LL, Roubenoff R, Hesse LM, Harmatz JS, Shader RI, Greenblatt DJ. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol. 2003;56:297\u2013304.","journal-title":"Br J Clin Pharmacol"},{"key":"19_CR31","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s00228-006-0155-6","volume":"62","author":"A Tornio","year":"2006","unstructured":"Tornio A, Neuvonen PJ, Backman JT. The CYP2C8 inhibitor gemfibrozil does not increase the plasma concentrations of zopiclone. Eur J Clin Pharmacol. 2006;62:645\u201351.","journal-title":"Eur J Clin Pharmacol"},{"key":"19_CR32","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1046\/j.1440-1819.2000.00634.x","volume":"54","author":"T Nakajima","year":"2000","unstructured":"Nakajima T, Takazawa S, Hayashida S, Nakagome K, Sasaki T, Kanno O. Effects of zolpidem and zopiclone on cognitive and attentional function in young healthy volunteers: an event-related potential study. Psychiatry Clin Neurosci. 2000;54:37\u201340.","journal-title":"Psychiatry Clin Neurosci"},{"key":"19_CR33","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1046\/j.1365-2125.1997.00579.x","volume":"43","author":"K Villikka","year":"1997","unstructured":"Villikka K, Kivist\u00f6 KT, Lamberg TS, Kantola T, Neuvonen PJ. Concentrations and effects of zopiclone are greatly reduced by rifampicin. Br J Clin Pharmacol. 1997;43:471\u20134.","journal-title":"Br J Clin Pharmacol"},{"key":"19_CR34","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1365-2125.2005.02380.x","volume":"60","author":"T Tokairin","year":"2005","unstructured":"Tokairin T, Fukasawa T, Yasui-Furukori N, Aoshima T, Suzuki A, Inoue Y, Tateishi T, Otani K. Inhibition of the metabolism of brotizolam by erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in brotizolam metabolism. Br J Clin Pharmacol. 2005;60:172\u20135.","journal-title":"Br J Clin Pharmacol"},{"key":"19_CR35","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/j.1365-2125.2004.02208.x","volume":"58","author":"T Osanai","year":"2004","unstructured":"Osanai T, Ohkubo T, Yasui N, Kondo T, Kaneko S. Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. Br J Clin Pharmacol. 2004;58:476\u201381.","journal-title":"Br J Clin Pharmacol"},{"key":"19_CR36","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1177\/009127009803801207","volume":"38","author":"JM Gerven van","year":"1998","unstructured":"van Gerven JM, Uchida E, Uchida N, Pieters MS, Meinders AJ, Schoemaker RC, Nanhekhan LV, Kroon JM, de Visser SJ, Altorf B, Yasuda K, Yasuhara H, Cohen AF. Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers. J Clin Pharmacol. 1998;38:1129\u201336.","journal-title":"J Clin Pharmacol"},{"key":"19_CR37","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/j.1365-2125.1986.tb02934.x","volume":"22","author":"DR Abernethy","year":"1986","unstructured":"Abernethy DR, Greenblatt DJ, Locniskar A, Ochs HR, Harmatz JS, Shader RI. Obesity effects on nitrazepam disposition. Br J Clin Pharmacol. 1986;22:551\u20137.","journal-title":"Br J Clin Pharmacol"},{"key":"19_CR38","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/clpt.1985.248","volume":"38","author":"DJ Greenblatt","year":"1985","unstructured":"Greenblatt DJ, Abernethy DR, Locniskar A, Ochs HR, Harmatz JS, Shader RI. Age, sex, and nitrazepam kinetics: relation to antipyrine disposition. Clin Pharmacol Ther. 1985;38:697\u2013703.","journal-title":"Clin Pharmacol Ther"},{"key":"19_CR39","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s00228-005-0071-1","volume":"62","author":"K Sugimoto","year":"2006","unstructured":"Sugimoto K, Araki N, Ohmori M, Harada K, Cui Y, Tsuruoka S, Kawaguchi A, Fujimura A. Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol. 2006;62:209\u201315.","journal-title":"Eur J Clin Pharmacol"},{"key":"19_CR40","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1097\/00004850-199705000-00006","volume":"12","author":"K Otani","year":"1997","unstructured":"Otani K, Yasui N, Furukori H, Kaneko S, Tasaki H, Ohkubo T, Nagasaki T, Sugawara K, Hayashi K. Relationship between single oral dose pharmacokinetics of alprazolam and triazolam. Int Clin Psychopharmacol. 1997;12:153\u20137.","journal-title":"Int Clin Psychopharmacol"},{"key":"19_CR41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0278-5846(02)00357-3","volume":"27","author":"T Aoshima","year":"2003","unstructured":"Aoshima T, Fukasawa T, Otsuji Y, Okuyama N, Gerstenberg G, Miura M, Ohkubo T, Sugawara K, Otani K. Effects of the CYP2C19 genotype and cigarette smoking on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:535\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"19_CR42","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3109\/00498258509045357","volume":"15","author":"A Mancinelli","year":"1985","unstructured":"Mancinelli A, Guiso G, Garattini S, Urso R, Caccia S. Kinetic and pharmacological studies on estazolam in mice and man. Xenobiotica. 1985;15:257\u201365.","journal-title":"Xenobiotica"},{"key":"19_CR43","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1046\/j.1440-172x.2001.00269.x","volume":"7","author":"D Evans","year":"2001","unstructured":"Evans D, Hodgkinson B, Lambert L, Wood J. Falls risk factors in the hospital setting: a systematic review. Int J Nurs Pract. 2001;7:38\u201345.","journal-title":"Int J Nurs Pract"},{"key":"19_CR44","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1136\/bmj.39049.706493.55","volume":"334","author":"D Oliver","year":"2007","unstructured":"Oliver D, Connelly JB, Victor CR, Shaw FE, Whitehead A, Genc Y, Vanoli A, Martin FC, Gosney MA. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta-analyses. BMJ. 2007;334:82\u20138.","journal-title":"BMJ"},{"key":"19_CR45","first-page":"517","volume":"76","author":"K Ramakrishnan","year":"2007","unstructured":"Ramakrishnan K, Scheid DC. Treatment options for insomnia. Am Fam Physician. 2007;76:517\u201326.","journal-title":"Am Fam Physician"},{"key":"19_CR46","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1254\/fpj.119.111","volume":"119","author":"K Shirakawa","year":"2002","unstructured":"Shirakawa K. Pharmacological profile and clinical effect of zolpidem (Myslee tablets), a hypnotic agent. Folia Pharmacol Jpn. 2002;119:111\u20138.","journal-title":"Folia Pharmacol Jpn"},{"key":"19_CR47","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1177\/026988119901300109","volume":"13","author":"G Darcourt","year":"1999","unstructured":"Darcourt G, Pringuey D, Salliere D, Lavoisy J. The safety and tolerability of zolpidem\u2014an update. J Psychopharmacol. 1999;13:81\u201393.","journal-title":"J Psychopharmacol"},{"key":"19_CR48","first-page":"192","volume":"55","author":"MB Scharf","year":"1994","unstructured":"Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry. 1994;55:192\u20139.","journal-title":"J Clin Psychiatry"},{"key":"19_CR49","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1124\/pr.108.00505","volume":"60","author":"RW Olsen","year":"2000","unstructured":"Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol Rev. 2000;60:243\u201360.","journal-title":"Pharmacol Rev"},{"key":"19_CR50","first-page":"181","volume":"47","author":"W Sieghart","year":"1995","unstructured":"Sieghart W. Structure and pharmacology of gamma-aminobutyric acid(A) receptor subtypes. Pharmacol Rev. 1995;47:181\u2013234.","journal-title":"Pharmacol Rev"},{"key":"19_CR51","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1126\/science.2551039","volume":"245","author":"DB Pritchett","year":"1989","unstructured":"Pritchett DB, L\u00fcddens H, Seeburg PH. Type I and Type II GABAA-benzodiazepine receptors produced in transfected cells. Science. 1989;245:1389\u201392.","journal-title":"Science"},{"key":"19_CR52","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1111\/j.1471-4159.1990.tb01237.x","volume":"54","author":"DB Pritchett","year":"1990","unstructured":"Pritchett DB, Seeburg PH. \u03b3-Aminobutyric acidA receptor \u03b15-subunit creates novel type II benzodiazepine receptor pharmacology. J Neurochem. 1990;54:1802\u20134.","journal-title":"J Neurochem"},{"key":"19_CR53","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/0149-7634(94)90049-3","volume":"18","author":"DJ Sanger","year":"1994","unstructured":"Sanger DJ, Benavides J, Perrault G, Morel E, Cohen E, Joly D, Zivkovic B. Recent developments in the behavioral pharmacology of benzodiazepine (v) receptors: evidence for the functional significance of receptors subtypes. Neurosci Biobehav Rev. 1994;18:335\u201372.","journal-title":"Neurosci Biobehav Rev"},{"key":"19_CR54","first-page":"1253","volume":"23","author":"L Pichard","year":"1995","unstructured":"Pichard L, Gillet G, Bonfils C, Domergue J, Th\u00e9not JP, Maurel P. Oxidative metabolism of zolpidem by human liver cytochrome P450S. Drug Metab Dispos. 1995;23:1253\u201362.","journal-title":"Drug Metab Dispos"},{"key":"19_CR55","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/bdd.329","volume":"23","author":"LL Moltke von","year":"2002","unstructured":"von Moltke LL, Weemhoff JL, Perloff MD, Hesse LM, Harmatz JS, Roth-Schechter BF, Greenblatt DJ. Effect of zolpidem on human cytochrome P450 activity, and on transport mediated by P-glycoprotein. Biopharm Drug Dispos. 2002;23:361\u20137.","journal-title":"Biopharm Drug Dispos"},{"key":"19_CR56","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1124\/dmd.108.021816","volume":"36","author":"M Miyazaki","year":"2008","unstructured":"Miyazaki M, Nakamura K, Fujita Y, Guengerich FP, Horiuchi R, Yamamoto K. Defective activity of recombinant cytochromes P450 3A4.2 and 3A4.16 in oxidation of midazolam, nifedipine, and testosterone. Drug Metab Dispos. 2008;36:2287\u201391.","journal-title":"Drug Metab Dispos"},{"key":"19_CR57","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2165\/00003495-200059040-00014","volume":"59","author":"KJ Holm","year":"2000","unstructured":"Holm KJ, Goa KL. Zolpidem: an update of its pharmacology, therapeutic efficacy and tolerability in the treatment of insomnia. Drugs. 2000;59:865\u201389.","journal-title":"Drugs"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-013-0019-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0019-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-013-0019-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T08:51:56Z","timestamp":1715503916000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-013-0019-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":57,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["19"],"URL":"https:\/\/doi.org\/10.1007\/s40268-013-0019-3","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}